Lisata Therapeutics, Inc. (NASDAQ:LSTA) Sees Large Decline in Short Interest

Lisata Therapeutics, Inc. (NASDAQ:LSTA) was the recipient of a large decline in short interest in the month of December. As of December 31st, there was short interest totalling 16,400 shares, a decline of 14.1% from the December 15th total of 19,100 shares. Based on an average daily volume of 25,600 shares, the short-interest ratio is presently 0.6 days. Currently, 0.2% of the shares of the company are short sold.

Institutional Trading of Lisata Therapeutics

An institutional investor recently raised its position in Lisata Therapeutics stock. Dimensional Fund Advisors LP boosted its holdings in shares of Lisata Therapeutics, Inc. (NASDAQ:LSTA) by 48.2% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 17,336 shares of the company’s stock after purchasing an additional 5,639 shares during the period. Dimensional Fund Advisors LP owned about 0.21% of Lisata Therapeutics worth $60,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 8.94% of the company’s stock.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a “buy” rating and set a $15.00 target price on shares of Lisata Therapeutics in a report on Wednesday, December 11th.

Lisata Therapeutics Stock Performance

Shares of LSTA remained flat at $3.72 during trading hours on Thursday. The stock had a trading volume of 50,009 shares, compared to its average volume of 84,891. Lisata Therapeutics has a 12 month low of $2.19 and a 12 month high of $4.20. The stock has a market capitalization of $31.21 million, a P/E ratio of -1.48 and a beta of 1.14. The business’s fifty day simple moving average is $3.00 and its two-hundred day simple moving average is $3.06.

Lisata Therapeutics (NASDAQ:LSTA) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.59) earnings per share for the quarter, topping the consensus estimate of ($0.75) by $0.16. During the same quarter in the prior year, the firm posted ($0.65) EPS. Analysts expect that Lisata Therapeutics will post -2.66 EPS for the current fiscal year.

Lisata Therapeutics Company Profile

Lisata Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease.